IXIA PLUS 20/25

Informació principal

  • Denominació comercial:
  • IXIA PLUS 20/25 mg 28 comprimidos recubiertos
  • formulario farmacéutico:
  • Comprimidos
  • Vía de administración:
  • Oral
  • Utilitza per:
  • Humans
  • Tipo de medicina:
  • medicament al·lopàtic

Documents

Localització

  • Disponible en:
  • IXIA PLUS 20/25 mg 28 comprimidos recubiertos
    Andorra
  • Idioma:
  • català

Altres dades

Estat

  • Font:
  • CedimCat - Centre d'Informació de Medicaments de Catalunya
  • Número d'autorització:
  • 654284
  • última actualització:
  • 08-06-2018

Prospecte: composició, indicacions, interacció, posologia, embaràs, lactància, reaccions adverses

IXIA PLUS 20/25 mg 28 comprimidos

recubiertos

olmesart

n+hidroclorotiazida

Indicacions

Medicament que augmenta la quantitat d'orina (DI

TIC) i ajuda a regular la pressi

sangu

(ANTIHIPERTENSIU).

Consideracions

NO prengui aquest medicament si

s al

rgic a SULFAMIDES.

Prengui els comprimits sencers, sense partir ni mastegar, empassant-los amb ajuda d'un got d'aigua.

Pot prendre aquest medicament amb o sense aliments; si t

sties d'est

mac, prengui'l amb

algun aliment.

s aconsellable que prengui aquest medicament al mat

o al migdia, per tal d'evitar haver d'aixecar-se

a la nit a orinar.

Tot i trobar-se millor, NO deixi de prendre aquest medicament durant el temps indicat pel seu metge.

Avisi el seu metge si pateix o ha patit problemes de cor, problemes de rony

o problemes de fetge.

Si vost

猫 茅

s diab

tic/a, tingui en compte que aquest medicament pot alterar els nivells de glucosa en

sang i orina.

Aquest medicament modifica l'acci

d'altres f

rmacs, NO prengui altres medicaments sense consultar

abans al seu metge o farmac

utic.

Durant el tractament, eviti aixecar-se de forma brusca per tal d'evitar possibles mareigs.

s possible que el seu metge li recomani una dieta especial, que conv

seguir per augmentar l'efic

cia d'aquest medicament.

NO utilitzi substituts de la sal de taula ni suplements de potassi sense coneixement del seu metge.

NO fumi NI begui mentre duri el tractament, d'aquesta manera augmentar

l'efic

cia d'aquest

medicament.

Mentre prengui aquest medicament procuri NO prendre grans quantitats de begudes amb cafe

na (caf

, te, refrescs de cola).

Informi immediatament el seu metge si est

embarassada o creu que pot estar-ho, aix

com si qued

s embarassada durant el tractament.

Avisi al seu metge si t

algun fill a qui estigui alletant.

Efectes adversos

Aquest medicament pot produir mareigs i sensaci

de cansament.

Si not

s qualsevol altre s

mptoma que creu que pot ser causat per aquest medicament, digui-li-ho al

seu metge.

Posologia

Prengui 1 comprimit a l'esmorzar.

VIA ORAL.

17-4-2019


Committee for Advanced Therapies (CAT): 23-25 January 2019, European Medicines Agency, London, UK, from 23/01/2019 to 25/01/2019

Committee for Advanced Therapies (CAT): 23-25 January 2019, European Medicines Agency, London, UK, from 23/01/2019 to 25/01/2019

Committee for Advanced Therapies (CAT): 23-25 January 2019, European Medicines Agency, London, UK, from 23/01/2019 to 25/01/2019

Europe - EMA - European Medicines Agency

17-4-2019


Committee for Advanced Therapies (CAT): 20-22 March 2019, European Medicines Agency, from 20/03/2019 to 22/03/2019

Committee for Advanced Therapies (CAT): 20-22 March 2019, European Medicines Agency, from 20/03/2019 to 22/03/2019

Committee for Advanced Therapies (CAT): 20-22 March 2019, European Medicines Agency, from 20/03/2019 to 22/03/2019

Europe - EMA - European Medicines Agency

16-4-2019

Jensen Tuna of Louisiana is Voluntarily Recalling Frozen Ground Tuna Imported from JK Fish, Because it may Potentially be Contaminated with <em>Salmonella</em>

Jensen Tuna of Louisiana is Voluntarily Recalling Frozen Ground Tuna Imported from JK Fish, Because it may Potentially be Contaminated with <em>Salmonella</em>

Jensen Tuna of Louisiana is Voluntarily Recalling Frozen Ground Tuna Imported from JK Fish, Because it may Potentially be Contaminated with Salmonella. The frozen product, individually packaged in clear plastic one-pound bags, is sold in white wax 20 lb. boxes. The product is only sold as a wholesale case with twenty bags in each case. The lot numbers are z266, z271 and z272.

FDA - U.S. Food and Drug Administration

12-4-2019

Outcome of a public consultation on the draft scientific opinion on the health risks related to the presence of cyanogenic glycosides in foods other than raw apricot kernels

Outcome of a public consultation on the draft scientific opinion on the health risks related to the presence of cyanogenic glycosides in foods other than raw apricot kernels

Published on: Thu, 11 Apr 2019 The European Food Safety Authority (EFSA) carried out a public consultation to receive input from the interested parties on a draft scientific opinion on the health risks related to the presence of cyanogenic glycosides in foods other than raw apricot kernels prepared by the EFSA Panel on Contaminants in the Food Chain (CONTAM Panel), supported by the Working Group on hydrocyanic acid in food. The draft opinion was endorsed by the CONTAM Panel for public consultation at it...

Europe - EFSA - European Food Safety Authority EFSA Journal

12-4-2019

Evaluation of the health risks related to the presence of cyanogenic glycosides in foods other than raw apricot kernels

Evaluation of the health risks related to the presence of cyanogenic glycosides in foods other than raw apricot kernels

Published on: Thu, 11 Apr 2019 In 2016, the EFSA Panel on Contaminants in the Food Chain (CONTAM) published a scientific opinion on the acute health risks related to the presence of cyanogenic glycosides (CNGs) in raw apricot kernels in which an acute reference dose (ARfD) of 20 μg/kg body weight (bw) was established for cyanide (CN). In the present opinion, the CONTAM Panel concluded that this ARfD is applicable for acute effects of CN regardless the dietary source. To account for differences in cyanid...

Europe - EFSA - European Food Safety Authority EFSA Journal

10-4-2019

Safety of whey basic protein isolate for extended uses in foods for special medical purposes and food supplements for infants pursuant to Regulation (EU) 2015/2283

Safety of whey basic protein isolate for extended uses in foods for special medical purposes and food supplements for infants pursuant to Regulation (EU) 2015/2283

Published on: Tue, 09 Apr 2019 In 2018, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) concluded that whey basic protein isolate obtained by ion exchange chromatography from skimmed cow's milk is safe for human consumption under the proposed conditions of use as infant and follow on formula, meal replacement beverages, foods for special medical purposes and food supplements. Following a request from the European Commission, the EFSA NDA Panel was asked to deliver a scientific opinion ...

Europe - EFSA - European Food Safety Authority EFSA Journal

28-3-2019

Blokhuis verscherpt regels en toezicht voor internetverkoop alcohol

Blokhuis verscherpt regels en toezicht voor internetverkoop alcohol

Verkopers van alcohol via internet zullen aan strengere regels moeten voldoen om de verkoop aan minderjarigen tegen te gaan. Het toezicht daarop wordt gecentraliseerd naar de Nederlandse Voedsel en Warenautoriteit (NVWA). Staatssecretaris Paul Blokhuis (VWS) start vandaag de consultatie van een wetsvoorstel waarmee deze nieuwe regels worden vastgelegd. Met hetzelfde wetsvoorstel wordt geregeld dat er een einde komt aan stuntaanbiedingen voor alcohol als ‘twee halen, één betalen’. Verkopers moeten aanbied...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

27-3-2019

Enforcement Report for the Week of March 27, 2019

Enforcement Report for the Week of March 27, 2019

Recently Updated Records for the Week of March 27, 2019 Last Modified Date: Wednesday, March 20, 2019

FDA - U.S. Food and Drug Administration

26-3-2019

April 25, 2019: Antimicrobial Drugs Advisory Committee Meeting Announcement

April 25, 2019: Antimicrobial Drugs Advisory Committee Meeting Announcement

April 25, 2019: Antimicrobial Drugs Advisory Committee Meeting Announcement

FDA - U.S. Food and Drug Administration

26-3-2019

EU Insights Chemical mixtures awareness, understanding and risk perceptions

EU Insights Chemical mixtures awareness, understanding and risk perceptions

Published on: Mon, 25 Mar 2019 EFSA defines ‘chemical mixtures’ as ‘several substances which may have combined effects on the body from their combined exposures’. There are already some methodologies for assessing risks from combined exposure to groups of chemicals, and EFSA together with European partners is developing methodologies to assess the risk from exposure to combinations of chemicals in food. However, consumers' understanding and views on this topic have not been documented. This poses signif...

Europe - EFSA - European Food Safety Authority EFSA Journal

26-3-2019

Guidance on harmonised methodologies for human health, animal health and ecological risk assessment of combined exposure to multiple chemicals

Guidance on harmonised methodologies for human health, animal health and ecological risk assessment of combined exposure to multiple chemicals

Published on: Mon, 25 Mar 2019 This Guidance document describes harmonised risk assessment methodologies for combined exposure to multiple chemicals for all relevant areas within EFSA's remit, i.e. human health, animal health and ecological areas. First, a short review of the key terms, scientific basis for combined exposure risk assessment and approaches to assessing (eco)toxicology is given, including existing frameworks for these risk assessments. This background was evaluated, resulting in a harmoni...

Europe - EFSA - European Food Safety Authority EFSA Journal

26-3-2019

Technical report of the public consultation on the draft ‘Guidance on harmonised risk assessment methodologies for human health, animal health and ecological risk assessment of combined exposure to multiple chemicals’

Technical report of the public consultation on the draft ‘Guidance on harmonised risk assessment methodologies for human health, animal health and ecological risk assessment of combined exposure to multiple chemicals’

Published on: Mon, 25 Mar 2019 The European Food Safety Authority (EFSA) carried out a public consultation to receive input from the scientific community and all interested parties on the draft guidance of the working group of the Scientific Committee ‘Harmonised risk assessment methodologies for human health, animal health and ecological risk assessment of combined exposure to multiple chemicals’. The background and the Terms of Reference were prepared by EFSA staff and the working group of the Scienti...

Europe - EFSA - European Food Safety Authority EFSA Journal

21-3-2019

FDA Announces New Date for Webinar on Genome Editing in Animals

FDA Announces New Date for Webinar on Genome Editing in Animals

On April 25, 2019, FDA CVM, with participation from the CBER, will hold a public webinar about genome editing in animals, an innovative and rapidly evolving technology that offers significant public health benefits.

FDA - U.S. Food and Drug Administration

21-3-2019

Modification of the existing maximum residue levels for pyridaben in tomatoes and aubergines

Modification of the existing maximum residue levels for pyridaben in tomatoes and aubergines

Published on: Wed, 20 Mar 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant Nissan Chemical Europe S.A.S. submitted a request to the competent national authority in the Netherlands to modify the existing maximum residue levels (MRLs) for the active substance pyridaben in tomatoes and aubergines. An MRL proposal of 0.15 mg/kg was derived for tomatoes and aubergines which reflects the intended use of the plant protection product containing pyridaben. Adequate analytical metho...

Europe - EFSA - European Food Safety Authority EFSA Journal

21-3-2019

Modification of the existing maximum residue level for cyprodinil in Florence fennel

Modification of the existing maximum residue level for cyprodinil in Florence fennel

Published on: Wed, 20 Mar 2019 In accordance with Article 6 of Regulation (EC) No 396/2005, the FPS Health, Food chain safety and Environment of Belgium, submitted an application to modify the existing maximum residue level (MRL) for the active substance cyprodinil in Florence fennel to accommodate the intended use in the northern Europe. The submitted data were found sufficient to derive an MRL proposal of 4 mg/kg for cyprodinil in Florence fennel. Adequate analytical methods for enforcement are availa...

Europe - EFSA - European Food Safety Authority EFSA Journal

21-3-2019

Safety and efficacy of Cinergy® Life B3 HiCon (Bacillus amyloliquefaciens NRRL B‐50508, B. amyloliquefaciens NRRL B‐50509 and Bacillus subtilis NRRL B‐50510) as a feed additive for pigs for fattening and minor porcine species

Safety and efficacy of Cinergy® Life B3 HiCon (Bacillus amyloliquefaciens NRRL B‐50508, B. amyloliquefaciens NRRL B‐50509 and Bacillus subtilis NRRL B‐50510) as a feed additive for pigs for fattening and minor porcine species

Published on: Wed, 20 Mar 2019 The additive contains viable spores of two strains of Bacillus amyloliquefaciens and a single strain of Bacillus subtilis and is intended to be used with pigs for fattening and minor porcine species at a minimum inclusion level of 1.5 × 108 colony forming units (CFU)/kg complete feedingstuffs. The two bacterial species are considered suitable for the qualified presumption of safety (QPS) approach to safety assessment, which requires the identity of the strains to be establ...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-3-2019

Enforcement Report for the Week of March 20, 2019

Enforcement Report for the Week of March 20, 2019

Recently Updated Records for the Week of March 20, 2019 Last Modified Date: Monday, March 18, 2019

FDA - U.S. Food and Drug Administration

20-3-2019

Safety and efficacy of eight compounds belonging to different chemical groups when used as flavourings for cats and dogs

Safety and efficacy of eight compounds belonging to different chemical groups when used as flavourings for cats and dogs

Published on: Tue, 19 Mar 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of 23 compounds belonging to different chemical groups. This opinion concerns eight out of the 23 compounds, which are currently authorised for use as flavours in food. The Panel concludes that the eight additives are safe for cats and dogs at the proposed use level: phenyl...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-3-2019

Safety and efficacy of 26 compounds belonging to chemical group 3 (α,β‐unsaturated straight‐chain and branched‐chain aliphatic primary alcohols, aldehydes, acids and esters) when used as flavourings for all animal species and categories

Safety and efficacy of 26 compounds belonging to chemical group 3 (α,β‐unsaturated straight‐chain and branched‐chain aliphatic primary alcohols, aldehydes, acids and esters) when used as flavourings for all animal species and categories

Published on: Tue, 19 Mar 2019 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of 26 compounds belonging to chemical group 3 (α,β‐unsaturated straight‐chain and branched‐chain aliphatic primary alcohols, aldehydes, acids and esters). They are all currently authorised as flavours in food. The FEEDAP Panel was unable to perform the assessment of non‐2(c...

Europe - EFSA - European Food Safety Authority EFSA Journal

18-3-2019

Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter

Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate Matter

Mylan Institutional LLC is conducting a voluntary nationwide recall of two lots (see table below) of Levoleucovorin Injection, 250 mg/25 mL to the consumer/user level. The lots were manufactured by Alidac Pharmaceuticals Limited and distributed by Mylan Institutional LLC.

FDA - U.S. Food and Drug Administration

16-3-2019

Efficacy of sodium formate as a technological feed additive (hygiene condition enhancer) for all animal species

Efficacy of sodium formate as a technological feed additive (hygiene condition enhancer) for all animal species

Published on: Fri, 15 Mar 2019 In 2015, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) issued an opinion on the safety and efficacy of formic acid, ammonium formate and sodium formate as feed hygiene agents for all animal species. In this opinion, two forms of the additive sodium formate, a solid form (specified to contain ≥ 98% sodium formate (w/w)) and a liquid form (specified to contain a minimum of 15% sodium formate, a maximum of 75% free formic acid and a maxim...

Europe - EFSA - European Food Safety Authority EFSA Journal

16-3-2019

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmace

Legacy Pharmaceutical Packaging, LLC Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25mg, 50mg, And 100mg Due to The Detection of Trace Amounts Of N-Nitroso N-Methyl 4-Amino Butyric Acid (NMBA) Impurity Found in The Active Pharmace

Earth City, MO, Legacy Pharmaceutical Packaging, LLC is recalling 40 repackaged lots of Losartan Tablets USP 25mg, 50mg, and 100mg to the consumer level. This recall was prompted due to Camber Pharmaceuticals, Inc. issuing a Voluntary Nationwide Recall of Losartan Tablets, USP, due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, (API manufacturer).

FDA - U.S. Food and Drug Administration

13-3-2019

Hometown Food Company Recalls Two Production LOT Codes of Pillsbury® Unbleached All-Purpose 5lb Flour Due to Possible Health Risk

Hometown Food Company Recalls Two Production LOT Codes of Pillsbury® Unbleached All-Purpose 5lb Flour Due to Possible Health Risk

Please be advised the Hometown Food Company initiated a limited, voluntary retail-level recall on two specific lot codes of its Pillsbury® Unbleached All-Purpose 5 lb Flour (UPC 51500-22241) because it may be contaminated with Salmonella. Only Best If Used By Dates APR 19 2020 and APR 20 2020 are impacted.

FDA - U.S. Food and Drug Administration

12-3-2019


Agenda - CAT agenda of the 20-22 February 2019 meeting

Agenda - CAT agenda of the 20-22 February 2019 meeting

Agenda - CAT agenda of the 20-22 February 2019 meeting

Europe - EMA - European Medicines Agency

9-3-2019

Safety evaluation of the food enzyme 4‐α‐glucanotransferase from Aeribacillus pallidus (strain AE‐SAS)

Safety evaluation of the food enzyme 4‐α‐glucanotransferase from Aeribacillus pallidus (strain AE‐SAS)

Published on: Fri, 08 Mar 2019 The food enzyme 4‐α‐glucanotransferase (1,4‐α‐d‐glucan:1,4‐α‐d‐glucan 4‐α‐d‐glycosyltransferase, EC 2.4.1.25) is produced with a non‐genetically modified Aeribacillus pallidus (previously identified as Geobacillus pallidus) strain from Amano Enzyme Inc. The food enzyme is intended to be used in baking processes and in starch processing for the production of modified dextrins. For baking processes, based on the maximum use levels recommended and individual data from the EFS...

Europe - EFSA - European Food Safety Authority EFSA Journal

7-3-2019

Re‐evaluation of Quillaia extract (E 999) as a food additive and safety of the proposed extension of use

Re‐evaluation of Quillaia extract (E 999) as a food additive and safety of the proposed extension of use

Published on: Wed, 06 Mar 2019 The EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS) provides a scientific opinion on Quillaia extract (E 999) when used as a food additive and the evaluation of the safety of its proposed extension of use as a food additive in flavourings. The Scientific Committee for Food (SCF) in 1978 established an acceptable daily intake (ADI) of 0–5 mg spray‐dried extract/kg body weight (bw) per day for E 999. The Joint FAO/WHO Expert Committee on Food Additives ...

Europe - EFSA - European Food Safety Authority EFSA Journal

1-3-2019

Pest categorisation of Thrips palmi

Pest categorisation of Thrips palmi

Published on: Thu, 28 Feb 2019 The EFSA Panel on Plant Health (PLH) performed a pest categorisation of Thrips palmi(Thysanoptera: Thripidae), for the EU. T. palmi is listed in Annex IAI of 2000/29 EC. Using molecular methods, cryptic speciation has been shown although no new species from the group have been formally described. Here, we consider T. palmi sensu lato as a defined species native to southern Asia, which has spread to tropical and subtropical countries in Asia, the Pacific, North, Central and...

Europe - EFSA - European Food Safety Authority EFSA Journal

1-3-2019

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25 mg, 50 mg and 100 mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25 mg, 50 mg and 100 mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical

Camber Pharmaceuticals, Inc. is recalling 87 lots of Losartan Tablets USP 25 mg, 50 mg, and 100 mg to consumer level. This recall was prompted due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, Unit – I (API manufacturer).

FDA - U.S. Food and Drug Administration

27-2-2019

Enforcement Report for the Week of February 27, 2019

Enforcement Report for the Week of February 27, 2019

Recently Updated Records for the Week of February 27, 2019 Last Modified Date: Wednesday, February 20, 2019

FDA - U.S. Food and Drug Administration

26-2-2019

Safety and efficacy of TYFER™ (ferric tyrosine chelate) as a zootechnical feed additive for chickens, turkeys and minor poultry species for fattening or reared for laying/breading

Safety and efficacy of TYFER™ (ferric tyrosine chelate) as a zootechnical feed additive for chickens, turkeys and minor poultry species for fattening or reared for laying/breading

Published on: Mon, 25 Feb 2019 Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of the product TYFER™ (ferric tyrosine chelate) as zootechnical feed additive for chickens, turkeys and minor poultry species for fattening or reared for laying/breeding. The additive is safe for chickens for fattening at the maximum expected level of 200 mg TYFER™/kg complete feed; this conclusion can be extended to chickens reared for laying/breedin...

Europe - EFSA - European Food Safety Authority EFSA Journal

26-2-2019

Safety and efficacy of a molybdenum compound (E7) sodium molybdate dihydrate as feed additive for sheep based on a dossier submitted by Trouw Nutrition International B.V.

Safety and efficacy of a molybdenum compound (E7) sodium molybdate dihydrate as feed additive for sheep based on a dossier submitted by Trouw Nutrition International B.V.

Published on: Mon, 25 Feb 2019 No abstract available. © European Food Safety Authority, 2015 Safety and efficacy of a molybdenum compound (E7) sodium molybdate dihydrate as feed additive for sheep based on a dossier submitted by Trouw Nutrition International B.V.

Europe - EFSA - European Food Safety Authority EFSA Journal

25-2-2019

Macleods Pharmaceuticals Limited Issues Voluntary Nationwide Consumer Level Recall of One Lot (BLM 715A) of Losartan Potassium/Hydrochlorothiazide Combination Tablets 100mg/25mg Due to detection of NDEA (N-Nitrosodiethylamine) Impurity

Macleods Pharmaceuticals Limited Issues Voluntary Nationwide Consumer Level Recall of One Lot (BLM 715A) of Losartan Potassium/Hydrochlorothiazide Combination Tablets 100mg/25mg Due to detection of NDEA (N-Nitrosodiethylamine) Impurity

Macleods Pharmaceuticals Limited is voluntarily recalling one lot of Losartan Potassium/Hydrochlorothiazide combination tablets 100mg/25mg to the consumer level due to the detection of trace amounts of an unexpected impurity (NDEA) found in finished product manufactured with active pharmaceutical ingredient made by Hetero Labs Limited.

FDA - U.S. Food and Drug Administration

12-4-2019


Orphan designation: 4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine x HC1, Treatment of Huntington's disease, 20/06/2005, Positive

Orphan designation: 4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine x HC1, Treatment of Huntington's disease, 20/06/2005, Positive

Orphan designation: 4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine x HC1, Treatment of Huntington's disease, 20/06/2005, Positive

Europe - EMA - European Medicines Agency

12-4-2019


Orphan designation: Recombinant human minibody against complement component C5 fused with RGD-motif, Prevention of the ischaemia/reperfusion injury associated with solid organ transplantation, 20/01/2009, Withdrawn

Orphan designation: Recombinant human minibody against complement component C5 fused with RGD-motif, Prevention of the ischaemia/reperfusion injury associated with solid organ transplantation, 20/01/2009, Withdrawn

Orphan designation: Recombinant human minibody against complement component C5 fused with RGD-motif, Prevention of the ischaemia/reperfusion injury associated with solid organ transplantation, 20/01/2009, Withdrawn

Europe - EMA - European Medicines Agency

12-4-2019


Referral: Lemtrada,  alemtuzumab, Article 20 procedures, Procedure started

Referral: Lemtrada,  alemtuzumab, Article 20 procedures, Procedure started

Referral: Lemtrada,  alemtuzumab, Article 20 procedures, Procedure started

Europe - EMA - European Medicines Agency

8-4-2019


Orphan designation: N-[(1R)-1-phenylethyl]-6-{1H-pyrazolo[3,4-d]pyrimidin-4-yl}quinazolin-2-amine, Treatment of fragile X syndrome, 20/04/2017, Positive

Orphan designation: N-[(1R)-1-phenylethyl]-6-{1H-pyrazolo[3,4-d]pyrimidin-4-yl}quinazolin-2-amine, Treatment of fragile X syndrome, 20/04/2017, Positive

Orphan designation: N-[(1R)-1-phenylethyl]-6-{1H-pyrazolo[3,4-d]pyrimidin-4-yl}quinazolin-2-amine, Treatment of fragile X syndrome, 20/04/2017, Positive

Europe - EMA - European Medicines Agency

3-4-2019

Submissions received: Fees and charges proposal 2019-20

Submissions received: Fees and charges proposal 2019-20

We thank those individuals and organisations who lodged submissions for their valuable contribution

Therapeutic Goods Administration - Australia

29-3-2019


Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 March 2019

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 March 2019

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 March 2019

Europe - EMA - European Medicines Agency

28-3-2019


20 years of sampling and testing of centrally authorised products: 1998 – 2017

20 years of sampling and testing of centrally authorised products: 1998 – 2017

20 years of sampling and testing of centrally authorised products: 1998 – 2017

Europe - EMA - European Medicines Agency

28-3-2019


20 years of sampling and testing programme for medicines authorised for the EU

20 years of sampling and testing programme for medicines authorised for the EU

20 years of sampling and testing programme for medicines authorised for the EU

Europe - EMA - European Medicines Agency

21-3-2019

In addition, the FDA is providing a live feed of the meeting for those who cannot attend in person: March 25, 2019 (Day 1) Webcast:  https://bit.ly/2WgkmGC   March 26, 2019 (Day 2) Webcast: https://bit.ly/2TnAKU0   #FDA #MedicalDevicepic.twitter.com/zvhd7

In addition, the FDA is providing a live feed of the meeting for those who cannot attend in person: March 25, 2019 (Day 1) Webcast: https://bit.ly/2WgkmGC  March 26, 2019 (Day 2) Webcast: https://bit.ly/2TnAKU0  #FDA #MedicalDevicepic.twitter.com/zvhd7

In addition, the FDA is providing a live feed of the meeting for those who cannot attend in person: March 25, 2019 (Day 1) Webcast: https://bit.ly/2WgkmGC  March 26, 2019 (Day 2) Webcast: https://bit.ly/2TnAKU0  #FDA #MedicalDevice pic.twitter.com/zvhd72SyxX

FDA - U.S. Food and Drug Administration

21-3-2019

The @US_FDA is committed to protecting and promoting the public’s health. On March 25-26, the agency will host the General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee Meeting. #FDA #MedicalDevicepic.twitter.com/Wh9Sshjn6n

The @US_FDA is committed to protecting and promoting the public’s health. On March 25-26, the agency will host the General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee Meeting. #FDA #MedicalDevicepic.twitter.com/Wh9Sshjn6n

The @US_FDA is committed to protecting and promoting the public’s health. On March 25-26, the agency will host the General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee Meeting. #FDA #MedicalDevice pic.twitter.com/Wh9Sshjn6n

FDA - U.S. Food and Drug Administration

20-3-2019

EU/3/13/1154 (Diamond ROC EOOD)

EU/3/13/1154 (Diamond ROC EOOD)

EU/3/13/1154 (Active substance: Fosbretabulin tromethamine) - Transfer of orphan designation - Commission Decision (2019)2145 of Wed, 20 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003817

Europe -DG Health and Food Safety

18-3-2019


Orphan designation: Amikacin sulfate (liposomal), Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis, 25/07/2006, Positive

Orphan designation: Amikacin sulfate (liposomal), Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis, 25/07/2006, Positive

Orphan designation: Amikacin sulfate (liposomal), Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis, 25/07/2006, Positive

Europe - EMA - European Medicines Agency

13-3-2019

Cresemba (Basilea Pharmaceutica Deutschland GmbH)

Cresemba (Basilea Pharmaceutica Deutschland GmbH)

Cresemba (Active substance: isavuconazole) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)2069 of Wed, 13 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2734/T/20

Europe -DG Health and Food Safety

13-3-2019

Stayveer (Janssen Pharmaceutica N.V.)

Stayveer (Janssen Pharmaceutica N.V.)

Stayveer (Active substance: bosentan) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)2065 of Wed, 13 Mar 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/2644/T/25

Europe -DG Health and Food Safety

8-3-2019

Public submissions on scheduling matters referred to the ACMS #25, ACCS #23 and Joint ACMS-ACCS #20 meetings held in November 2018

Public submissions on scheduling matters referred to the ACMS #25, ACCS #23 and Joint ACMS-ACCS #20 meetings held in November 2018

Public submissions on scheduling matters referred to ACMS/ACCS meetings held in November 2018

Therapeutic Goods Administration - Australia

6-3-2019


Orphan designation: Avacopan, Treatment of C3 glomerulopathy, 20/06/2017, Positive

Orphan designation: Avacopan, Treatment of C3 glomerulopathy, 20/06/2017, Positive

Orphan designation: Avacopan, Treatment of C3 glomerulopathy, 20/06/2017, Positive

Europe - EMA - European Medicines Agency

25-2-2019

Vabomere (Menarini International Operations Luxembourg S.A.)

Vabomere (Menarini International Operations Luxembourg S.A.)

Vabomere (Active substance: meropenem/vaborbactam) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2019)1591 of Mon, 25 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/004669/T/0001

Europe -DG Health and Food Safety

25-2-2019

Zulvac BTV (Zoetis Belgium S.A.)

Zulvac BTV (Zoetis Belgium S.A.)

Zulvac BTV (Active substance: Bluetongue virus vaccine (inactivated) (multistrain: 1 strain out of a set of 3)) - Centralised - Variation - Commission Decision (2019)1607 of Mon, 25 Feb 2019 European Medicines Agency (EMA) procedure number: EMEA/V/C/4185/X/01

Europe -DG Health and Food Safety

25-2-2019

EU/3/17/1880 (Chemocentryx Ireland Limited)

EU/3/17/1880 (Chemocentryx Ireland Limited)

EU/3/17/1880 (Active substance: Avacopan) - Transfer of orphan designation - Commission Decision (2019)1618 of Mon, 25 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004221

Europe -DG Health and Food Safety

25-2-2019

EU/3/10/732 (Southwood Research Limited)

EU/3/10/732 (Southwood Research Limited)

EU/3/10/732 (Active substance: Entinostat) - Transfer of orphan designation - Commission Decision (2019)1631 of Mon, 25 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004131

Europe -DG Health and Food Safety

25-2-2019

EU/3/05/301 (Taro Pharmaceuticals Europe B.V.)

EU/3/05/301 (Taro Pharmaceuticals Europe B.V.)

EU/3/05/301 (Active substance: Chimeric monoclonal antibody to shiga-toxin 1 and 2) - Transfer of orphan designation - Commission Decision (2019)1636 of Mon, 25 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003835

Europe -DG Health and Food Safety

25-2-2019

EU/3/05/288 (Teva  GmbH)

EU/3/05/288 (Teva GmbH)

EU/3/05/288 (Active substance: 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine x HCl) - Transfer of orphan designation - Commission Decision (2019)1635 of Mon, 25 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003804

Europe -DG Health and Food Safety

25-2-2019

EU/3/16/1674 (Bellicum Pharma GmbH)

EU/3/16/1674 (Bellicum Pharma GmbH)

EU/3/16/1674 (Active substance: Allogeneic donor-derived ex-vivo expanded T lymphocytes transduced with a retroviral vector containing inducible caspase 9 and truncated CD19) - Transfer of orphan designation - Commission Decision (2019)1630 of Mon, 25 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004083

Europe -DG Health and Food Safety

25-2-2019

EU/3/16/1666 (Bellicum Pharma GmbH)

EU/3/16/1666 (Bellicum Pharma GmbH)

EU/3/16/1666 (Active substance: Rimiducid) - Transfer of orphan designation - Commission Decision (2019)1629 of Mon, 25 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004057

Europe -DG Health and Food Safety

25-2-2019

EU/3/15/1526 (Ultragenyx Netherlands B.V.)

EU/3/15/1526 (Ultragenyx Netherlands B.V.)

EU/3/15/1526 (Active substance: Triheptanoin) - Transfer of orphan designation - Commission Decision (2019)1632 of Mon, 25 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003558

Europe -DG Health and Food Safety

25-2-2019

EU/3/12/1091 (bluebird bio (Netherlands) B.V.)

EU/3/12/1091 (bluebird bio (Netherlands) B.V.)

EU/3/12/1091 (Active substance: Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human betaA-T87Q-globin gene) - Transfer of orphan designation - Commission Decision (2019)1626 of Mon, 25 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003556

Europe -DG Health and Food Safety

25-2-2019

EU/3/12/1003 (bluebird bio (Netherlands) B.V.)

EU/3/12/1003 (bluebird bio (Netherlands) B.V.)

EU/3/12/1003 (Active substance: Autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA) - Transfer of orphan designation - Commission Decision (2019)1634 of Mon, 25 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003636

Europe -DG Health and Food Safety

25-2-2019

EU/3/18/2026 (Alnylam Netherlands B.V.)

EU/3/18/2026 (Alnylam Netherlands B.V.)

EU/3/18/2026 (Active substance: Synthetic double-stranded siRNA oligonucleotide targeted against transthyretin mRNA, with six phosphorothioate linkages in the backbone, and nine 2'-fluoro and thirty-five 2'-O-methyl nucleoside residues in the sequence, which is covalently linked via a phosphodiester group to a ligand containing three N-acetylgalactosamine residues) - Transfer of orphan designation - Commission Decision (2019)1637 of Mon, 25 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/O...

Europe -DG Health and Food Safety

25-2-2019

EU/3/15/1518 (Novartis Europharm Limited)

EU/3/15/1518 (Novartis Europharm Limited)

EU/3/15/1518 (Active substance: Adenovirus-associated viral vector serotype 2 containing the human RPE65 gene) - Transfer of orphan designation - Commission Decision (2019)1628 of Mon, 25 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003549

Europe -DG Health and Food Safety

25-2-2019

EU/3/12/981 (Novartis Europharm Limited)

EU/3/12/981 (Novartis Europharm Limited)

EU/3/12/981 (Active substance: Adenovirus associated viral vector serotype 2 containing the human RPE65 gene) - Transfer of orphan designation - Commission Decision (2019)1627 of Mon, 25 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003485

Europe -DG Health and Food Safety

25-2-2019

EU/3/16/1637 (Alnylam Netherlands B.V.)

EU/3/16/1637 (Alnylam Netherlands B.V.)

EU/3/16/1637 (Active substance: Synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues) - Transfer of orphan designation - Commission Decision (2019)1633 of Mon, 25 Feb 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000003680

Europe -DG Health and Food Safety

25-2-2019

BLUEVAC BTV8 (CZ Veterinaria, S.A.)

BLUEVAC BTV8 (CZ Veterinaria, S.A.)

BLUEVAC BTV8 (Active substance: Bluetongue virus inactivated, serotype 8) - Centralised - Yearly update - Commission Decision (2019)1610 of Mon, 25 Feb 2019

Europe -DG Health and Food Safety